The SR-B1 Receptor as a Potential Target for Treating Glioblastoma.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
02
2019
revised:
22
04
2019
accepted:
12
05
2019
entrez:
6
7
2019
pubmed:
6
7
2019
medline:
6
7
2019
Statut:
epublish
Résumé
The goal of these studies was to provide proof of concept for a novel targeted therapy for Findings from cytotoxicity studies indicate that the rHDL/EVR formulation was 185 times more potent than free EVR against high SR-B1 expressing cell line (LN 229). Cell cycle analysis revealed that rHDL/EVR treated LN229 cells had a 5.8 times higher apoptotic cell population than those treated with EVR. The sensitivity of GBM cells to EVR treatment was strongly correlated with SR-B1 expression. These studies present strong proof of concept regarding the efficacy of delivering EVR and likely other agents, via a biocompatible transport system, targeted to the SR-B1 receptor that is upregulated in most cancers, including GBM. Targeting the SR-B1 receptor could thus lead to effective personalized therapy of GBM.
Identifiants
pubmed: 31275377
doi: 10.1155/2019/1805841
pmc: PMC6583082
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1805841Références
J Neurochem. 2001 Jan;76(2):498-508
pubmed: 11208913
Am J Pathol. 2001 Mar;158(3):825-32
pubmed: 11238031
Anticancer Res. 2002 Jul-Aug;22(4):2045-9
pubmed: 12174882
Endocr Rev. 2003 Jun;24(3):357-87
pubmed: 12788804
Chemotherapy. 2006;52(4):171-3
pubmed: 16691026
J Control Release. 2007 Feb 26;117(3):301-11
pubmed: 17239472
Expert Opin Drug Deliv. 2007 Nov;4(6):665-75
pubmed: 17970668
Anticancer Drugs. 2008 Feb;19(2):183-8
pubmed: 18176115
J Drug Target. 2010 Jan;18(1):53-8
pubmed: 19637935
Neoplasia. 2011 Apr;13(4):309-19
pubmed: 21472135
Nanomedicine (Lond). 2011 Jun;6(4):631-41
pubmed: 21718175
Int J Nanomedicine. 2012;7:975-83
pubmed: 22393294
J Immunol. 2012 Apr 15;188(8):3988-92
pubmed: 22422884
Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2511-6
pubmed: 23345442
J Pathol. 2014 Jan;232(2):165-77
pubmed: 24114756
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Cancer Gene Ther. 2014 Feb;21(2):45-7
pubmed: 24535159
World J Clin Oncol. 2014 May 10;5(2):142-8
pubmed: 24829861
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 May-Jun;7(3):298-314
pubmed: 25346461
Neuro Oncol. 2015 Sep;17(9):1261-9
pubmed: 25526733
Cancer Res. 2015 Mar 1;75(5):808-12
pubmed: 25576083
Neuro Oncol. 2016 Feb;18(2):160-72
pubmed: 26180081
Reprod Biol Endocrinol. 2015 Aug 07;13:88
pubmed: 26251134
Tumour Biol. 2016 Mar;37(3):3581-8
pubmed: 26456958
Front Pharmacol. 2015 Oct 26;6:247
pubmed: 26578957
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1305-15
pubmed: 27174096
Cancer Res. 2016 Aug 15;76(16):4828-40
pubmed: 27199348
Front Pharmacol. 2016 Sep 27;7:326
pubmed: 27729859
Front Pharmacol. 2016 Dec 15;7:466
pubmed: 28018216
Target Oncol. 2017 Jun;12(3):323-332
pubmed: 28357727
Biochem Biophys Res Commun. 2018 Jan 1;495(1):614-620
pubmed: 29128352
Front Physiol. 2017 Oct 30;8:841
pubmed: 29163190
BMC Cancer. 2018 Jan 22;18(1):88
pubmed: 29357836
Nanomedicine (Lond). 2018 Mar;13(6):579-583
pubmed: 29376468
Sci Rep. 2018 Mar 14;8(1):4561
pubmed: 29540809
Biomater Sci. 2018 May 1;6(5):958-973
pubmed: 29564432
Front Pharmacol. 2018 Oct 15;9:1154
pubmed: 30374303
J Transl Int Med. 2018 Oct 09;6(3):128-133
pubmed: 30425948
Front Endocrinol (Lausanne). 2018 Nov 30;9:715
pubmed: 30555417
Nanomedicine (Lond). 2019 Mar;14(6):727-752
pubmed: 30574827
ACS Nano. 2019 Feb 26;13(2):1365-1384
pubmed: 30721028
PLoS One. 2019 Mar 19;14(3):e0213852
pubmed: 30889203
J Pharmacol Exp Ther. 2019 Jun;369(3):481-488
pubmed: 30971477